AstraZeneca has recorded $4 billion in revenue from COVID-19 vaccine sales.
The company developed its COVID-19 vaccine with the University of Oxford and saw full-year revenues of $37.4 billion — an increase of 38% since last year, according to a Thursday report.
AstraZeneca also announced a pretax loss of $265 million following the purchase of U.S. drug company Alexion Pharmaceuticals.
ROGAN DECLINES RUMBLE’S $100 MILLION OFFER: ‘SPOTIFY HAS HUNG WITH ME’
AstraZeneca CEO Pascal Soriot told the Associated Press that the company had “delivered on our promise of broad and equitable access to our COVID-19 vaccine with 2.5 billion doses released for supply around the world.”
AstraZeneca predicted in November that it would start taking a “modest” profit from its COVID-19 vaccine.
CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER
The company said Thursday that total group sales would rise by a “high teens percentage” in 2022 but that COVID-related revenues would drop by “a low-to-mid twenties percentage.”
